First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC) Article

Industry Collaboration

cited authors

  • Spigel, David R., Mekhail, Tarek M., Waterhouse, David, Hadley, Terence, Webb, Charles, Burris, Howard A., Hainsworth, John D., Greco, F. Anthony

funding text

  • This work was supported in part by a grant from Amgen.

abstract

  • Background: We added panitumumab to standard combination chemotherapy as first-line treatment for patients with advanced KRAS WT non-squamous NSCLC. Methods: Patients received panitumumab 9 mg/kg IV, pemetrexed 500 mg/m(2) IV, and carboplatin AUC = 6 IV every 21days. After 6 cycles, maintenance therapy with panitumumab and pemetrexed was administered every 21days until progressive disease or unacceptable toxicity. Results: 29 of 66 patients (44%) had objective responses. The median TTP was 6 months; median overall survival (OS) was 17 months. Panitumumab increased treatment-related toxicity, notably skin rash. Conclusions: The addition of panitumumab increased toxicity, and had no discernible impact on efficacy.

Publication Date

  • January 1, 2017

webpage

published in

category

start page

  • 541

end page

  • 546

volume

  • 35

issue

  • 8

WoS Citations

  • 1

WoS References

  • 19